Every year clinical trials of vital therapies are canceled, not because the therapy is not promising but because of issues with trial feasibility or cost. This hurts all stakeholders: pharmaceutical companies, healthcare providers, and especially patients. Making trials more cost-effective and feasible means improving the way participants are identified and enrolled while also cutting the time and labor of collecting data. Many researchers say real-world evidence in the form of multiple-source EDW data is the answer, though this requires bridging some gaps in interoperability and security. Learn from experts who work in all facets of clinical trials in this discussion of the promises and challenges of integrating EDW data into clinical trials.